ID2 and cancer: METTL3 May posttranscriptionally upregulate the levels of inhibitor of DNA binding 2 (ID2) in an m6A/YTHDF2-dependent mechanism, thereby enhancing ID2 mRNA stability and promoting cancer cell proliferative capacity [151].